These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 23034579)

  • 1. Interpreting results from Factor V Leiden mutation analysis: a cautionary note.
    Sinclair GD; Poon MC
    Clin Appl Thromb Hemost; 2013; 19(1):106-7. PubMed ID: 23034579
    [No Abstract]   [Full Text] [Related]  

  • 2. A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
    De Bel AV; Van der Cruyssen GA; Devreese KM
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):155-60. PubMed ID: 16479199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor V Leiden mutation in one family of Chinese origin.
    Wu J; Gu J; Xu J; Wang J; Sun Z; Smirnov MD; Morrissey JH; Esmon N
    Chin Med J (Engl); 2001 Apr; 114(4):379-81. PubMed ID: 11780458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of activated protein C resistance during menstrual cycle in women with and without the Leiden mutation.
    Wramsby ML; Bremme K; Blombäck M
    Thromb Haemost; 2001 Apr; 85(4):614-8. PubMed ID: 11341494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor V mutations in Iranian patients with activated protein C resistance and venous thrombosis.
    Chegeni R; Kazemi B; Hajifathali A; Pourfathollah A; Lari GR
    Thromb Res; 2007; 119(2):189-93. PubMed ID: 16542711
    [No Abstract]   [Full Text] [Related]  

  • 6. High prevalence of activated protein C resistance due to factor V leiden mutation in cases of intrauterine fetal death.
    Rothbart H; Ohel G; Younis J; Lanir N; Brenner B
    J Matern Fetal Med; 1999; 8(5):228-30. PubMed ID: 10475506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation factor V Leiden mutation was detected in the patients with activated protein C resistance in Thailand.
    Arnutti P; Hiyoshi M; Prayoonwiwat W; Nathalang O; Suwanasophon C; Kokaseam R; Tatsumi N
    Thromb Haemost; 1998 Aug; 80(2):344-5. PubMed ID: 9716166
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance.
    Mikovic D; Rakicevic L; Kovac M; Radojkovic D
    Thromb Haemost; 2000 Oct; 84(4):723-4. PubMed ID: 11057877
    [No Abstract]   [Full Text] [Related]  

  • 9. Perils in the thrombophilia workup: Frequency and circumstances of erroneously ordered factor V activity tests for thrombophilia.
    Houghton DE; Sud S; Moll S; Rollins-Raval MA
    Vasc Med; 2017 Dec; 22(6):527-528. PubMed ID: 28965480
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arterial vascular occlusion associated with factor V Leiden gene mutation.
    Tayyanipour R; Pulido JS; Postel EA; Lipkowitz JL; Pisciotta A; Braza E
    Retina; 1998; 18(4):376-7. PubMed ID: 9730184
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction.
    Middendorf K; Göhring P; Huehns TY; Seidel D; Steinbeck G; Nikol S
    Am Heart J; 2004 May; 147(5):897-904. PubMed ID: 15131548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral retinal vein occlusion associated with factor V Leiden mutation.
    Spagnolo BV; Nasrallah FP
    Retina; 1998; 18(4):377-8. PubMed ID: 9730185
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular implications of the factor V Leiden mutation.
    Major DA; Sane DC; Herrington DM
    Am Heart J; 2000 Aug; 140(2):189-95. PubMed ID: 10925328
    [No Abstract]   [Full Text] [Related]  

  • 15. [Mutation of factor V Leiden and chronic leg edema with chronic venous insufficiency and recurrent thromboses].
    Chanda RA
    Praxis (Bern 1994); 1999 Sep; 88(36):1449-50. PubMed ID: 10500421
    [No Abstract]   [Full Text] [Related]  

  • 16. [Is lifetime anticoagulation required in factor V Leiden mutation?].
    Pötzsch B
    Dtsch Med Wochenschr; 2003 Jul; 128(30):1617. PubMed ID: 12884152
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk factors for clinical manifestations in carriers of Factor V Leiden and prothrombin gene mutations.
    DeSancho MT; Berlus N; Christos PJ; Rand J
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):11-5. PubMed ID: 19474699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated protein C resistance, factor V Leiden, and retinal vessel occlusion.
    Ma AD; Abrams CS
    Retina; 1998; 18(4):297-300. PubMed ID: 9730170
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prevalence of genetic prothrombotic factors (factor V Leiden and II20210 prothrombin mutation) in glomerular nephropathies with or without thrombosis].
    Martínez Ara J; Gómez Rioja R; Riñón C; García Muñoz MS; Ruiz Caravaca ML; Miguel JL
    Nefrologia; 2000; 20(2):139-44. PubMed ID: 10853194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy].
    Magdelaine A; Soubrier F; Berkane N; Uzan S; Verdy E
    Ann Biol Clin (Paris); 1998; 56(4):445-50. PubMed ID: 9754280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.